Acquisition – Talk Bio

Revolution Medicines; RVMD; Merck; AbbVie; takeover talks; acquisition rumors; buyout speculation; Financial Times report; Wall Street Journal; J.P. Morgan Healthcare Conference; multibillion-dollar deal; oncology; RAS-driven cancers; daraxonrasib

Lilly to acquire Ventyx Biosciences for ~$1.2B to add oral NLRP3 and other inflammatory drugs

3 weeks ago talkbio0Tagged Acquisition, Autoimmune Diseases, cardiometabolic, Eli, Eli Lilly, Inflammatory disorder, Neuroinflammation, NLRP3 inhibitors, oral therapies, Ventyx Biosciences

Eli Lilly; Ventyx Biosciences; $1.2 billion; acquisition; NLRP3 inhibitors; VTX3232; VTX2735; inflammatory diseases; oral therapies; cardiometabolic; neuroinflammation; autoimmune diseases

Amgen Acquires Oxford Spinout Dark Blue Therapeutics for Up to $840 Million, Gaining Preclinical Cancer Drug

3 weeks ago talkbio0Tagged Acquisition, Acute lymphocytic leukemia, amgen, AML, CSNK1E gene, Dark Blue Therapeutics, Leukemia, Myelocytic, Acute, Oxford spinout, protein degrader

Amgen; Dark Blue Therapeutics; acquisition; Oxford spinout; DBT 3757; AML; ALL; protein degrader

BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion

1 month ago talkbio0Tagged Acquisition, Amicus Therapeutics, BioMarin, Galafold, Infrequent, Opfolda, Pombiliti +

BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases

Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

1 month ago talkbio0Tagged Acquisition, brensocatib, Brinsupri, Chronic sinusitis, DPP1 inhibitor, Insmed, mid-stage trial, Nasal inflammation, Nasal Polyps, stocks, Trial failure

Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition

Pharmas Write Big M&A Checks Again as Patent Urgency Seizes C-Suites

1 month ago talkbio0Tagged 2025, Acquisition, Acquisitions, fibroblast growth factor 21, Health care facility, Johnson & Johnson Intra-Cellular, M&A, MASH, Merck Verona, Patent Cliff, Pharma, pharma patent expirations, Sanofi Blueprint Medicines

pharma M&A 2025; biotech acquisitions; patent cliff; pharma patent expirations; Novo Nordisk Akero deal; Johnson & Johnson Intra-Cellular acquisition; Merck Verona Pharma deal; Sanofi Blueprint Medicines acquisition; FGF21 MASH deals; 2025 healthcare deals

Sobi Acquires Arthrosi Therapeutics for $950M Upfront in Gout Drug Deal

1 month ago talkbio0Tagged Acquisition, Arthrosi, Gout, pozdeutinurad, Sobi

Sobi; Arthrosi Therapeutics; acquisition; gout; pozdeutinurad; AR882